A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Public ClinicalTrials.gov record NCT07733765. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA). This study is seeking participants who are * 12 years or older (if permitted by the local IRB/EC and local regulatory health authority) * have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less * do not have any other diseases or conditions affecting hair loss. Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks. About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone. We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.
Study identification
- NCT ID
- NCT07733765
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 336 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2026 (Actual)
- Primary completion
- Apr 26, 2028 (Estimated)
- Completion
- Apr 26, 2028 (Estimated)
- Last update posted
- Sep 10, 2026
2026 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024 | Not yet recruiting |
| Skin Research of South Florida | Miami | Florida | 33173 | Recruiting |
| Endeavor Health | Skokie | Illinois | 60077 | Not yet recruiting |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | Recruiting |
| University of Iowa | Iowa City | Iowa | 52242 | Not yet recruiting |
| Cutaneous Translational Research Program (CTReP) | Baltimore | Maryland | 21287 | Not yet recruiting |
| Johns Hopkins Hospital Investigational Drug Services (IDS) Pharmacy | Baltimore | Maryland | 21287 | Not yet recruiting |
| Revival Research Institute, LLC | Troy | Michigan | 48084 | Recruiting |
| Clinical and Translational Research Center (CTRC) | Chapel Hill | North Carolina | 27514 | Not yet recruiting |
| UNC Dermatology and Skin Cancer Center | Chapel Hill | North Carolina | 27516 | Not yet recruiting |
| Bexley Dermatology Research | Bexley | Ohio | 43209 | Not yet recruiting |
| NW Dermatology Institute | Portland | Oregon | 97210 | Not yet recruiting |
| Dermatology Associates of Plymouth Meeting | Plymouth Meeting | Pennsylvania | 19462 | Recruiting |
| Center for Clinical Studies, LTD. LLP | Houston | Texas | 77004 | Not yet recruiting |
| Texas Dermatology and Laser Specialists | San Antonio | Texas | 78218 | Recruiting |
| Dermatology Specialists of Spokane | Spokane | Washington | 99202 | Not yet recruiting |
| Principle Research Solutions | Spokane | Washington | 99202 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07733765, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07733765 live on ClinicalTrials.gov.